XOMA Corporation (XOMA)
Automate Your Wheel Strategy on XOMA
With Tiblio's Option Bot, you can configure your own wheel strategy including XOMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XOMA
- Rev/Share 3.0526
- Book/Share 7.0707
- PB 3.6064
- Debt/Equity 1.3524
- CurrentRatio 5.541
- ROIC -0.0293
- MktCap 305155950.0
- FreeCF/Share -0.5586
- PFCF -45.641
- PE -106.7539
- Debt/Assets 0.538
- DivYield 0
- ROE -0.0325
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | XOMA | The Benchmark Company | -- | Buy | -- | $35 | April 17, 2025 |
News
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
XOMA Royalty (XOMA) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.86 per share a year ago.
Read More
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025.
Read More
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock:
Read More
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D-Fi (FCX-007), Castle Creek's lead candidate, in patients with dystrophic epidermolysis bullosa (DEB).
Read More
About XOMA Corporation (XOMA)
- IPO Date 1986-06-06
- Website https://www.xoma.com
- Industry Biotechnology
- CEO Mr. Owen P. Hughes Jr.
- Employees 13